Neuvivo
- Vern Norviel
Vern Norviel is a Partner Emeritus at Wilson Sonsini Goodrich & Rosati, a position held since January 2002. As Founder and Board Member of Neuvivo and an Advisor and Adjunct Professor at Stanford University School of Medicine since October 2023, Vern is involved in the innovative MTRAM program. Additional roles include serving as Strategic Advisor at the Ellison Institute of Technology Los Angeles, Special Adviser at Appletree Partners, and a member of the Board of Trustees at the University of Colorado. Vern also contributes as a TAP Board Member for The Leukemia & Lymphoma Society, Chairman of the Morris Animal Foundation, a Lecturer at the University of California, San Francisco in a Global Entrepreneurship Course, and as a member of the Board of Overseers at Scripps Research.
Org chart
Upgrade to view 0 reports
Teams
This person is not in any teams
Offices
This person is not in any offices
Neuvivo
Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS. NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need. We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS.
